Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15485592 | 0.98 | HRH3 (0.52) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15485534 | 0.93 | HRH3 (0.61) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL23191089 | 0.93 | — | — | |
| SCHEMBL1037242 | 0.85 | HRH3 (0.48) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL20858732 | 0.85 | HRH3 (0.48) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL25432585 | 0.85 | HRH3 (0.48) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL15485864 | 0.82 | SMN1; SMN2 (0.52) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5325568 | 0.82 | MAPT (0.44) | HRH3MAPTSIGMAR1 | |
| SCHEMBL25433068 | 0.82 | POLB (0.48) | HRH3MAPTSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3770379 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| CN-105189478-B | Uracil deoxyriboside triphosphatase inhibitor | 南加州大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-105111151-B | Aminopyridine derivative as PPAR- gamma modulators | 成都理工大学 | 2018-09-28 | — | — | CN | disclosed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180140695-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-24 | — | — | US | disclosed |
| US-9907847-B2 | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases | GLAXOSMITHKLINE LLC (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2922549-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170080085-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9540383-B2 | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases | GLAXOSMITHKLINE LLC (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016107536-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | 南京明德新药研发股份有限公司 | 2016-07-07 | — | — | WO | disclosed |
| CN-105732635-A | Toll-like receptor 7 agonist | 南京明德新药研发股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-105111151-A | Aminopyrimidine derivative used as PPAR-gamma regulator | UNIV CHENGDU TECHNOLOGY | 2015-12-02 | — | — | CN | disclosed |
| US-20150284396-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2015-10-08 | — | — | US | disclosed |
| EP-2922549-A1 | NOVEL COMPOUNDS | Glaxosmithkline LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | HRH3 3648/4885MAPT 1448/4885CYP1A2 3771/4885 |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | TLR7, TLR9, TLR1 | HRH3 42/4885MAPT 4366/4885CYP1A2 2547/4885 |
| US-20150284396-A1 | NOVEL COMPOUNDS | IFNG, IFNAR1, IRF3 | HRH3 7/4885MAPT 4842/4885CYP1A2 1671/4885 |
| US-20170080085-A1 | NOVEL COMPOUNDS | IFNG, IFNAR1, IRF3 | HRH3 7/4885MAPT 4842/4885CYP1A2 1671/4885 |
| US-20180140695-A1 | NOVEL COMPOUNDS | IFNG, IFNAR1, IRF3 | HRH3 7/4885MAPT 4842/4885CYP1A2 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.